{"id": "5296", "url": "https://fevir.net/resources/Citation/5296", "date": "2021-10-25T15:17:23.312Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/preprint-citation"], "versionId": "21", "lastUpdated": "2025-10-13T09:55:39.733Z"}, "title": "PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint", "author": [{"name": "Brian S. Alper"}], "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "summary": [{"text": "Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT) [Preprint]. Contributors: Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki, Tariq A. Madani. In: OSF Preprints, DOI 10.31219/osf.io/urb6f. Published August 03, 2020. Available at: https://doi.org/10.31219/osf.io/urb6f.", "style": {"coding": [{"code": "comppub", "system": "http://hl7.org/fhir/citation-summary-style", "display": "Computable Publishing"}]}}, {"text": "Koshak, A. E., Koshak, E. A., Mobeireek, A. F., Badawi, M. A., Wali, S. O., Malibary, H. M., \u2026 Madani, T. A. (2020, August 3). Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT). https://doi.org/10.31219/osf.io/urb6f", "style": {"text": "APA", "coding": [{"code": "apa7", "system": "http://hl7.org/fhir/citation-summary-style", "display": "American Psychological Association 7th edition"}]}}, {"text": "Koshak, Abdulrahman E., et al. \u201cNigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT).\u201d OSF Preprints, 3 Aug. 2020. Web.", "style": {"text": "MLA", "coding": [{"code": "defined-in-text", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Defined in text"}]}}, {"text": "Koshak, Abdulrahman E., Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, et al. 2020. \u201cNigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT).\u201d OSF Preprints. August 3. doi:10.31219/osf.io/urb6f.", "style": {"text": "Chicago", "coding": [{"code": "chicago-a-17", "system": "http://hl7.org/fhir/citation-summary-style", "display": "Chicago Style Version 17 Author Date"}]}}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "5296", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "program", "system": "http://terminology.hl7.org/CodeSystem/usage-context-type", "display": "Program"}, "valueCodeableConcept": {"text": "MCBK Example"}}, {"code": {"code": "fevir-platform-use", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"code": "project-specific", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Project Specific"}]}}], "description": "A preprint that has only an abstract and data is different than CT.gov results", "resourceType": "Citation", "citedArtifact": {"title": [{"text": "Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT)", "type": [{"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/title-type", "display": "Primary title"}]}], "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}}], "abstract": [{"text": "Background\nEffective treatment for patients with the novel Coronavirus Disease (COVID-19) is desperately needed and is under rigorous research. Nigella sativa oil (NSO), a herbal medicine, that has a documented wide antiviral and immunomodulatory activities offering a therapeutic potential for COVID-19.\n\nMethods\nAdult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS\u00ae Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202.\n\nFindings\nA total of 94 patients were enrolled. Their mean age was 35 (SD=11) years old and 57% of them were male. There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001). Additionally, there was a significant difference in the average recovery time among both groups, 9 (SD=3) versus 11 (SD=3) days (p=0.003). Furthermore, 2 patients from the control group required hospitalization within the study period versus none in the treatment group. Adverse events were reported in 3 patients of NSO recipients as gastrointestinal symptoms.\n\nConclusions\nIn this RCT of adult patients with mild COVID-19, NSO was associated with a significant increase in the likelihood of recovery and a decrease in the likelihood of hospitalization. To our knowledge, this is the first RCT that shows potential therapeutic benefits of NSO in patients with COVID-19 which requires further confirmation with larger double-blinded RCTs.", "type": {"coding": [{"code": "primary-human-use", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type", "display": "Primary human use"}]}, "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}, "copyright": "CC-By Attribution 4.0 International"}], "relatesTo": [{"type": "transformed-into", "display": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint", "classifier": [{"coding": [{"code": "fhir-resource", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "FHIR Resource"}]}, {"text": "Evidence", "coding": [{"code": "Evidence", "system": "http://hl7.org/fhir/fhir-types", "display": "Evidence"}]}], "targetReference": {"identifier": {"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "6513", "system": "https://fevir.net", "assigner": {"display": "Computable Publishing LLC"}}, "reference": "https://fevir.net/resources/Evidence/6513"}}, {"type": "transformed-into", "display": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint", "classifier": [{"coding": [{"code": "fhir-resource", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "FHIR Resource"}]}, {"text": "Evidence", "coding": [{"code": "Evidence", "system": "http://hl7.org/fhir/fhir-types", "display": "Evidence"}]}], "targetReference": {"identifier": {"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "6514", "system": "https://fevir.net", "assigner": {"display": "Computable Publishing LLC"}}, "reference": "https://fevir.net/resources/Evidence/6514"}}, {"type": "transformed-into", "display": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint", "classifier": [{"coding": [{"code": "fhir-resource", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "FHIR Resource"}]}, {"text": "Evidence", "coding": [{"code": "Evidence", "system": "http://hl7.org/fhir/fhir-types", "display": "Evidence"}]}], "targetReference": {"identifier": {"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "6512", "system": "https://fevir.net", "assigner": {"display": "Computable Publishing LLC"}}, "reference": "https://fevir.net/resources/Evidence/6512"}}], "identifier": [{"value": "10.31219/osf.io/urb6f", "system": "https://doi.org"}], "webLocation": [{"url": "https://doi.org/10.31219/osf.io/urb6f", "classifier": [{"coding": [{"code": "doi-based", "system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "display": "DOI Based"}]}]}, {"url": "https://osf.io/urb6f/", "classifier": [{"coding": [{"code": "abstract", "system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "display": "Abstract"}]}]}], "classification": [{"type": {"coding": [{"code": "knowledge-artifact-type", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Knowledge Artifact Type"}]}, "classifier": [{"coding": [{"code": "D000076942", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Preprint"}]}]}, {"type": {"text": "Study Type", "coding": [{"code": "study-design", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Study Design"}]}, "classifier": [{"text": "Randomized Controlled Trial", "coding": [{"code": "SEVCO:01003", "system": "https://fevir.net/sevco", "display": "randomized assignment"}]}]}], "contributorship": {"summary": [{"type": {"coding": [{"code": "author-string", "system": "http://hl7.org/fhir/contributor-summary-type", "display": "Author string"}]}, "value": "Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki, Tariq A. Madani", "source": {"coding": [{"code": "article-copy", "system": "http://hl7.org/fhir/contributor-summary-source", "display": "Copied from article"}]}}]}, "publicationForm": [{"language": [{"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}], "copyright": "CC-By Attribution 4.0 International", "pageCount": "2 pages", "articleDate": "2020-08-03", "publishedIn": {"type": {"coding": [{"code": "D019991", "system": "http://terminology.hl7.org/CodeSystem/published-in-type", "display": "Database"}]}, "title": "OSF Preprints"}}], "relatedIdentifier": [{"value": "NCT04401202", "system": "https://clinicaltrials.gov", "assigner": {"display": "NLM"}}]}}